In a statement, Daniel Salter, acting special agent in charge of the DEA's Dallas Field Division, said, "This settlement reinforces the responsibilities of all pharmacies to prevent the diversion of dangerous drugs." He added, "This case highlights DEA’s steadfast resolve to combat the growing prescription drug abuse problem in this country by ensuring that all DEA registrants, including nationwide pharmacy chains, are in compliance with the law. "
The pharmacy maintains the alleged violations were purely administrative.
"Neither the DEA nor the U.S. Attorney claimed that any patient’s health or safety was put at risk or that any false or fraudulent prescriptions for controlled substances were filled," CVS spokeswoman Carolyn Castel said in a statement to The Hill.
Castel added, "CVS/pharmacy has developed and implemented a new, state-of-the-art retail electronic prescription management and recordkeeping system at a cost of several hundred million dollars that is designed to comply with DEA and other regulatory requirements."
As a part of the settlement, CVS did not admit liability.